Monopar Therapeutics (Monopar Therapeutics) Quality Rank

View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Monopar Therapeutics Quality Rank Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Monopar Therapeutics (Monopar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

1IY:Germany

Address

1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091

Website

https://www.monopartx.com

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Executives

Michael J Brown	director	C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner	director	ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson	director	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto	officer: Chief Financial Officer	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson	director, officer: Chief Executive Officer	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Andrew Cittadine	officer: Chief Operating Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Patrice Rioux	other: Acting Chief Medical Officer	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr	director	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa	officer: Chief Medical Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc	10 percent owner	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson	officer: SVP, Clinical Development	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc	10 percent owner	C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc	10 percent owner	1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091